title: Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
abstract: OBJECTIVE
  The prevalence of non-alcoholic fatty liver disease (NAFLD) appears to be increasing. The aim of the present study was to investigate the relationship between hepatic antioxidant paraoxonase 1 (PON1) activity, lipid peroxidation and antioxidant enzymes in patients with NAFLD and the effect of atorvastatin.
  
  
  METHODS
  This study was conducted on 50 patients with NAFLD and 20 normal subjects matched for age and sex. All of them were subjected to the following investigations: abdominal ultrasonography, serum PON1 activity level, liver function tests, serum lipid profile, fasting and postprandial blood glucose and serum levels of malondialdehyde (MDA) and glutathione peroxidase (GP). NAFLD patients were further randomly classified into two groups (25 patients each), groups Ia and Ib. Only group Ia received atorvastatin 40mg tablet for 8months.
  
  
  RESULTS
  Obesity, dyslipidaemia and impaired glucose tolerance were prevalent in group I. There was a significant decrease in serum PON1 activity with a significant increase in MDA and GP activity (i.e., there is a significant increase in lipid peroxidation rate) in group I compared with group II. After atorvastatin therapy, there was a significant increase in serum PNO1 activity and significant decrease in serum MDA levels.
  
  
  CONCLUSIONS
  Patients with NAFLD show enhanced oxidative stress which may lead to non-alcoholic steatohepatitis (NASH). Reduced PON1 activity and increased MDA could be considered a biochemical marker for lipid peroxidation, which require follow-up in patients with NAFLD. Atorvastatin may have a role in prevention of, or delay, the transformation of liver steatosis into NASH.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
authors.forename: Waleed
authors.initials: W
authors.lastname: Samy
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Hassanian
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000097:blood* / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000097:blood; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005234:Fatty Liver / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood* / Q000187:drug effects; D006505:Hepatitis / Q000517:prevention & control; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity; D018384:Oxidative Stress / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011758:Pyrroles; D014280:Triglycerides; D008315:Malondialdehyde; D002784:Cholesterol; D000069059:Atorvastatin; D005979:Glutathione Peroxidase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D043303:Aryldialkylphosphatase